Compare Stocks: URGN, CRNX, ALKS, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.06 -0.8%	$49.98	$25.17 ▼ $55.67	$8.30B	0.34	1.71 million shs	1.27 million shs
CRNX Crinetics Pharmaceuticals	$84.70 +0.3%	$63.99	$28.73 ▼ $84.71	$8.96B	0.12	2.77 million shs	2.28 million shs
LQDA Liquidia	$74.44 +3.2%	$78.67	$21.15 ▼ $93.61	$6.41B	0.58	1.63 million shs	2.52 million shs
URGN Urogen Pharma	$48.22 +0.2%	$38.53	$15.86 ▼ $49.67	$2.35B	1.57	878,770 shs	458,057 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.79%	-0.22%	-5.62%	+30.90%	+71.36%
CRNX Crinetics Pharmaceuticals	+0.31%	+0.74%	+0.95%	+130.35%	+181.49%
LQDA Liquidia	+3.25%	-17.49%	-4.26%	+30.76%	+195.40%
URGN Urogen Pharma	+0.21%	+2.68%	+21.16%	+67.55%	+139.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$49.06 -0.8%	$49.98	$25.17 ▼ $55.67	$8.30B	0.34	1.71 million shs	1.27 million shs
CRNX Crinetics Pharmaceuticals	$84.70 +0.3%	$63.99	$28.73 ▼ $84.71	$8.96B	0.12	2.77 million shs	2.28 million shs
LQDA Liquidia	$74.44 +3.2%	$78.67	$21.15 ▼ $93.61	$6.41B	0.58	1.63 million shs	2.52 million shs
URGN Urogen Pharma	$48.22 +0.2%	$38.53	$15.86 ▼ $49.67	$2.35B	1.57	878,770 shs	458,057 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.79%	-0.22%	-5.62%	+30.90%	+71.36%
CRNX Crinetics Pharmaceuticals	+0.31%	+0.74%	+0.95%	+130.35%	+181.49%
LQDA Liquidia	+3.25%	-17.49%	-4.26%	+30.76%	+195.40%
URGN Urogen Pharma	+0.21%	+2.68%	+21.16%	+67.55%	+139.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	11.22% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.37% Downside
LQDA Liquidia	2.64	Moderate Buy	$98.08	31.76% Upside
URGN Urogen Pharma	2.82	Moderate Buy	$48.78	1.16% Upside

Current Analyst Ratings Breakdown

Latest URGN, CRNX, ALKS, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	LQDA Liquidia	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$79.00 ➝ $92.00
8/12/2026	LQDA Liquidia	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$109.00 ➝ $111.00
8/12/2026	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $110.00
8/12/2026	LQDA Liquidia	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Hold	$90.00
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/6/2026	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $58.00
8/6/2026	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $75.00
8/5/2026	URGN Urogen Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $60.00
7/30/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	5.58	$1.63 per share	30.03	$10.78 per share	4.55
CRNX Crinetics Pharmaceuticals	$7.70M	1,166.77	N/A	N/A	$11.24 per share	7.54
LQDA Liquidia	$158.32M	41.81	N/A	N/A	$0.51 per share	145.96
URGN Urogen Pharma	$188.73M	12.49	N/A	N/A	($2.71) per share	-17.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	129.11	204.42	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	N/A
LQDA Liquidia	-$68.92M	$0.14	54.34	14.02	N/A	30.74%	237.10%	41.36%	N/A
URGN Urogen Pharma	-$153.49M	-$1.98	N/A	13.82	N/A	-51.73%	N/A	-43.79%	N/A

Latest URGN, CRNX, ALKS, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/5/2026	Q2 2026	URGN Urogen Pharma	-$0.2650	-$0.28	-$0.0150	-$0.28	$63.55 million	$72.46 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LQDA Liquidia	1.18	2.22	2.03
URGN Urogen Pharma	N/A	3.80	3.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
CRNX Crinetics Pharmaceuticals	98.51%
LQDA Liquidia	64.54%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
CRNX Crinetics Pharmaceuticals	3.80%
LQDA Liquidia	25.60%
URGN Urogen Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
LQDA Liquidia	50	88.93 million	66.16 million	Optionable
URGN Urogen Pharma	200	48.88 million	46.54 million	Optionable

URGN, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice

August 14 at 1:01 PM | zacks.com

UroGen (URGN) Q2 2026 Earnings Call Transcript

August 12 at 11:33 PM | finance.yahoo.com

Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Time to Buy?

August 12 at 12:59 PM | marketbeat.com

Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

August 10, 2026 | marketbeat.com

UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus

August 9, 2026 | finance.yahoo.com

Urogen Pharma $URGN Shares Purchased by Hennion & Walsh Asset Management Inc.

August 9, 2026 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Price Target Raised to $75.00

August 9, 2026 | americanbankingnews.com

UroGen Pharma Ltd URGN

August 8, 2026 | morningstar.comM

Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright

August 6, 2026 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - What's Next?

August 6, 2026 | marketbeat.com

Urogen Pharma Q2 Earnings Call Highlights

August 5, 2026 | marketbeat.com

UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 5, 2026 | marketbeat.com

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

August 5, 2026 | markets.businessinsider.com

Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why

August 5, 2026 | marketbeat.com

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

August 5, 2026 | zacks.com

Swiss National Bank Makes New $1.40 Million Investment in Urogen Pharma $URGN

August 1, 2026 | marketbeat.com

UroGen Pharma (NASDAQ:URGN) Approaches A Defining Results Update

July 31, 2026 | kalkinemedia.comK

Urogen Pharma (URGN) to Announce Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Healthcare of Ontario Pension Plan Trust Fund Sells 738,026 Shares of Urogen Pharma $URGN

July 30, 2026 | marketbeat.com

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

July 30, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

URGN, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

$49.06 -0.39 (-0.79%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$51.23 +2.17 (+4.43%)

As of 08/14/2026 07:58 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.70 +0.26 (+0.31%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$84.68 -0.02 (-0.03%)

As of 08/14/2026 07:34 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Liquidia NASDAQ:LQDA

$74.44 +2.34 (+3.25%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$76.33 +1.89 (+2.53%)

As of 08/14/2026 07:55 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Urogen Pharma NASDAQ:URGN

$48.22 +0.10 (+0.21%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$48.22 0.00 (0.00%)

As of 08/14/2026 07:55 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest URGN, CRNX, ALKS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest URGN, CRNX, ALKS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

URGN, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

URGN, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest URGN, CRNX, ALKS, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest URGN, CRNX, ALKS, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

URGN, CRNX, ALKS, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

URGN, CRNX, ALKS, and LQDA Company Descriptions

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Liquidia NASDAQ:LQDA

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools